Escient Pharmaceuticals launched today with the completion of a $40 million Series A financing to advance first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic…